Background: Biomimetic nanoparticles are engineered by combining natural cell membranes with drug delivery nanoparticles to mimic autologous cells for immune evasion and prolonged blood circulation [1].Cell membrane-coated nanoparticles commonly exploit the passive targeting enhanced permeability and retention (EPR) effect to efficiently access tumor tissues.By leveraging the ligand-receptor interaction, the modification of cell membrane proteins enables them to selectively bind to tumor molecules, thereby greatly enhancing drug delivery efficiency.Our preliminary studies showed elevated chemokine CXCL12 secretion in the tumor microenvironment.CXCL12 specifically binds to the transmembrane receptor CXCR4 and plays an important role in tumor growth and metastasis.Based on this, modifying cell membranes to enhance CXCR4 expression may serve as an effective means to target tumor regions characterized by elevated CXCL12 secretion, thereby enabling precise diagnosis and targeted drug delivery.Ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation.Increasing evidence shows the potential of regulating ferroptosis in cancer therapy.The ferroptosis inducer RSL3 inhibits glutathione peroxidase 4 (GPX4) activity and interferes with its catalytic redox glutathione, thereby hindering the reduction process of intracellular lipid peroxide [2].Nevertheless, its poor solubility and inconsistent drug distribution in the bloodstream present constraints on its clinical utility [3].Therefore, encapsulating the RSL3 molecule within cell membrane-coated nanoparticles may improve its bioavailability.In the meanwhile, studies have found that the heat generated during photothermal therapy not only enhances the consumption of intracellular reducing glutathione but also accelerates the Fenton reaction, leading to increased lipid peroxide accumulation[4], [5].Thus, combining photothermal therapy with RSL3 may synergistically enhance ferroptosis in tumors.This project aims to construct a modified cell membrane-coated photosensitive nanoparticle loaded with a ferroptosis inducer.This drug delivery system is designed to actively target tumor sites as well as synergistically enhance ferroptotic tumor cell death. Methods:The chemokine receptor CXCR4 is overexpressed on the cell membrane through lentivirus transfection and is validated by RT-qPCR and western blotting.The migration ability of CXCR4-overexpressed cells towards CXCL12 is validated by a transwell migration assay.RSL3 is loaded into near-infrared responsive nanoparticles through solvent diffusion and is then encapsulated with CXCR4-overexpressed cell membranes (CXCR4-MNVs).The photothermal effect of CXCR4-MNVs is recorded by a thermal imaging camera.The tumor-targeting ability of CXCR4-MNVs is validated in vivo and the ferroptotic effect of CXCR4-MNVs on tumor cells is evaluated by functional assays. Results:We successfully constructed CXCR4-overexpressed cells and validated their enhanced chemoattraction towards CXCL12.The in vivo results displayed that CXCR4-MNVs can reach tumor regions with minimal off-target effects.When exposed to near-infrared light, the NPs' temperature was raised to over 50 °C.The cell viability assay and lipid peroxidation assay showed that near-infrared light irradiation and RSL3 synergistically inhibited tumor cell growth through ferroptosis.NDDTE 104-2 Conclusion:These results demonstrate the specific targeting and ferroptosis-enhancing capabilities of CXCR4-MNVs within tumor cells.This suggests that the CXCR4-MNVs system might be a potential treatment modality for cancer.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: